Clinical Trial Update: Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-B15/KEYNOTE-B15/EV-304 evaluating perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy for cisplatin-eligib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bladder Cancer | Phase 3 | Status: COMPLETED